| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
The increase in obesity is a social problem and the development of new therapeutic agents is desired. Fibroblast growth factor 21 (FGF21) has anti-obesity effects and may mediate the hypothalamic neuropeptide corticotropin-releasing hormone (CRH). This study investigated the mechanism of FGF21 action. Although the present study did not demonstrate the direct involvement of CRH in the FGF21 mechanism of action, several interesting hypothalamic gene (Acbd4, Glud1) alterations were observed. Further studies are needed to elucidate the full picture of FGF21 central nervous system actions.
|
